Aytug UNER, Mustafa TAHTACI, Gözde TAHTACI, Nazan GÜNEL

Glioblastoma Multiforme’de Ortalama Platelet Hacminin Prognostik Değeri

Amaç: Glioblastoma multiforme (GBM) en sık görülen primer malign beyin tümörüdür. Optimal tedaviye rağmen (maksimal cerrahi rezeksiyon, adjuvan radyoterapi ve kemoterapi) prognoz oldukça kötüdür. Bilinen prognostik faktörlerin yanı sıra, tanı anında nüksü öngörmek için herhangi bir yöntem yoktur. Bu çalışmada GBM'de ortalama trombosit hacmininin (MPV) prognoz ile ilişkisini değerlendirmeyi amaçladık. Yöntem: Histopatolojik olarak GBM tanısı alan ve medikal onkoloji kliniğine başvuran 107 hasta çalışmaya dahil edildi. Hastaların tanı anındaki MPV değerleri kaydedildi. MPV'nin prognostik etkisini değerlendirmek için Kaplan- Meier yöntemi ve Cox regresyonu kullanıldı. Bulgular: Kaplan-Meier sağkalım eğrileri, yüksek MPV grubuna ait hastaların daha kısa sağkalıma sahip olduğunu gösterdi (14 ay vs 20 ay , P = 0.004).MPV, GBM’de bağımsız bir prognostik faktördür. Sonuç: GBM hastalarında, tedavi öncesi MPV değerleri prognostik olarak kullanılabilecek ucuz, kolay erişilebilir ve tekrarlanabilir bir testtir.

Prognostic Value of Mean Platelet Volume in Glioblastoma Multiforme

Objectives: Glioblastoma multiforme (GBM) is the most common primarymalignant brain tumor. Despite optimal treatment (maximal surgicalresection, adjuvant radiotherapy and chemotherapy), the prognosis is verypoor. Beside known prognostic factors, there is no method at the time ofdiagnosis to predict recurrence. We aimed to identify mean platelet volume(MPV) as an indicator of prognosis in GBM.Methods: One hundred and seven patients who were diagnosed with GBMhistopathologically, admitted to the medical oncology clinic were included.MPV values were recorded for all patients at diagnosis. Kaplan-Meier methodand Cox regression were used to evaluate the prognostic impact of MPV.Results: Kaplan-Meier survival curves showed that patients belonging to thehigh-MPV group had a worse median OS (14 month versus 20 month,P=0.004). MPV was an independent prognostic factor in GBM.Conclusions: MPV is a cheap, easily accessible and reproducible test that canbe used prognostically in GBM patients before treatment.

PDF

___

Alifieris C, Trafalis DT. Glioblastoma multiforme: Pathogenesis and treatment. Pharmacol Ther. 2015, 152: 63-82
Gittleman H, Lim D, Kattan MW,Chakravarti A, Gilbert MR, Lassman AB, Lo SS, Machtay M, Sloan AE, Sulman EP, et al. An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. Neuro Oncol. 2017, 19:669-77
Zhao H, Wang S, Song C, Zha Y, Li L. The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta- analysis. World J Surg Oncol. 2016, 14:261.
Mezouar S, Frère C, Darbousset R, Mege D, Crescence L, Dignat-George F, Panicot-Dubois L, Dubois C. Role of platelets in cancer and cancer-associated thrombosis: Experimental and clinical evidences. Thromb Res. 2016, 139: 65- 76.
Xie X, Zeng X, Cao S, Hu X, Shi Q, Li D, Zhou S, Gu P, Zhang Z. Elevated pretreatment platelet distribution width and platelet count predict poor prognosis in nasopharyngeal carcinoma. Oncotarget. 2017, 8:106089-106097
Zhou Q, Huang F, He Z, Zuo MZ. Clinicopathological and prognostic significance of platelet count in patients with ovarian cancer. Climacteric. 2018, 21: 60-8
Kimyon Cömert G, Türkmen O Kar İ, Sınacı S, Yılmaz Ergani S, Karalök A.et al. Independent predictors of survival in endometrium cancer: platelet-to- lymphocyte ratio and platelet/neutrophil/monocyte-to-lymphocyte ratio. J Turk Ger Gynecol Assoc. 2018, 19:78-86
Kılınçalp S, Ekiz F, Başar O, Ayte MR, Coban S, Yılmaz B, Altınbaş A, Başar N, Aktaş B, Tuna Y. et al. Mean platelet volume could be possible biomarker in early diagnosis and monitoring of gastric cancer. Platelets. 2014, 25:592-4
Wang X, Cui MM, Xu Y, Liu L, Niu Y, Liu T, Liu ZP, Wang RT, Yu KJ. Decreased mean platelet volume predicts poor prognosis in invasive bladder cancer. Oncotarget. 2017, 8:68115-22
Gao L, Zhang H, Zhang B, Zhang L, Wang C. Prognostic value of combination of preoperative platelet count and mean platelet volume in patients with resectable non-small cell lung cancer. Oncotarget. 2017, 8:15632-41
Sharma D, Brummel-Ziedins KE, Bouchard BA, Holmes CE. Platelets in tumor progression: a host factor that offers multiple potential targets in the treatment of cancer. J Cell Physiol. 2014, 229:1005-15.
Li N, Yu Z, Zhang X, Liu T, Sun YX, Wang RT, Yu KJ. Elevated mean platelet volume predicts poor prognosis in colorectal cancer. Sci Rep. 2017, 7: 10261
Gu M, Zhai Z, Huang L, Zheng W, Zhou Y, Zhu R, Shen F, Yuan C. Pre- treatment mean platelet volume associates with worse clinicopathologic features and prognosis of patients with invasive breast cancer. Breast Cancer. 2016, 23:752-60.
Yin JB, Wang X, Zhang X, Liu L,Wang RT. Mean platelet volume predicts survival in pancreatic cancer patients with synchronous liver metastases. Sci Rep. 2018, 8: 6014
Yan M, Jurasz P. The role of platelets in the tumor microenvironment: from solid tumors to leukemia. Biochim Biophys Acta. 2016, 1863:392-400
Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol. 2006, 1:97-117.
Di Vito C, Navone SE, Marfia G, Abdel Hadi L, Mancuso ME, Pecci A, Crisà FM, Berno V, Rampini P,Campanella R.et al. Platelets from glioblastoma patients promote angiogenesis of tumor endothelial cells and exhibit increased VEGF content and release. Platelets. 2017, 28: 585-94.
Brockmann MA, Giese A, Mueller K, Kaba FJ, Lohr F,Weiss C, Gottschalk S, Nolte I, Leppert J, Tuettenberg J. et al. Preoperative thrombocytosis predicts poor survival in patients with glioblastoma. Neuro-oncology. 2007, 9:335-42.
Boonyawan K, Hess KR, Yang J, Long L, Wang Q, Ezhilarasan R, Auia A, Alfaro-Munoz KD, de Groot JF, Bhat KP, Sulman EP. A relative increase in circulating platelets following chemoradiation predicts for poor survival of patients with glioblastoma. Oncotarget.2017, 8:90488-95